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Figure 1. Schematic Showing Kinetic Stabilization of FMDV by Mutation
The parent virus is in red and the virus with acidic-to-neutral mutation is in blue. The associated state, but
not the transition state (z) for irreversible dissociation into pentamers, is stabilized by themutations, result-
ing in increased kinetic stability of the capsid.
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Previewsmolecules. More generally, the results
provide interesting new insights into
how nature has designed giant macro-
molecular assemblies of incredibly beau-
tiful symmetries that are poised at just
the right amount of (in)stability for
optimal function. And, for those of us
attempting to build biomaterials from
self-assembling proteins de novo, it is a1550 Structure 22, November 4, 2014 ª2014humbling view of the design processes
involved.
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In an important addition to the chemokine field, Millard and colleagues, in this issue of Structure, report the
first structure of a CC chemokine in complex with a sulfated peptide derived from its receptor.Due to its significant impact on health
and disease, the chemokine system
has been a target of interest for both
academic research and pharmaceutical
applications for years. The chemokinesystem, encompassing about 50 chemo-
kine proteins that selectively bind to
one or several cognate chemokine re-
ceptors, forms a sophisticated network
that is critical in the mammalian immunesystem, mediating activation and chemo-
taxis of leukocytes and playing a role
in both homing and inflammation.
Dysfunction in the chemokine system
has been implicated in health issues
Figure 1. Relative Orientation of a CC
Chemokine with Its Receptor, as Suggested
by the Structure of Millard et al. (2014)
CCL11 is shown as a space fillingmodel with critical
basic residuesArg16,Arg22,andLys47highlighted
in blue. The receptor peptide fromCCR3 (Su1617) is
shown inmagenta, and its two sulfated tyrosine res-
idues are shown as balls and sticks, clearly interact-
ing with CCL11. The structure of the CCR5 receptor
(Protein Data Bank [PDB] ID 4MBS, the only known
high resolution CC chemokine receptor structure
yet reported) is shown below CCL11 to indicate
theorientation of the chemokine relative to its recep-
tor as implied by the structure reported by Millard
et al. (2014) (PDB ID 2MPM). The dotted magenta
line indicates the possible trajectory of the N termi-
nus of the receptor as it binds a chemokine ligand.
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Previewsranging from heart disease to traumatic
brain injury to asthma (Charo and Ran-
sohoff, 2006).A total of four subfamilies of chemo-
kines have been identified, with the two
major ones being the CC and CXC
families. Chemokines from different
subfamilies bind to a distinct set of
receptors to function. Extensive effort
has been geared toward understanding
the chemokine:receptor interaction. To
date, many chemokine structures from
all four subfamilies have been reported,
because these ligands are generally small
proteins that are amenable to structural
study. In contrast, the chemokine recep-
tors are seven-transmembrane proteins
that have posed major challenges.
Recently, the field has been greatly
advanced by reports on the high resolu-
tion structures of several chemokine re-
ceptors bound with a small-molecule
antagonist or a peptide inhibitor, including
CXCR4 (Wu et al., 2010) and CCR5 (Tan
et al., 2013). Still, a critical gap remains
in understanding how the receptors
interact with their cognate chemokine
ligands.
While efforts to obtain a co-structure of
a chemokine in complex with its cognate
receptor are undoubtedly underway,
several groups have adopted a divide-
and-conquer strategy, in which chemo-
kines interacting with peptides corre-
sponding to the N-terminal portions of
their corresponding receptors were stud-
ied. More recent work also recognizes
the importance of sulfated tyrosines on
the receptors (Choe and Farzan, 2009).
Nuclear magnetic resonance (NMR) has
been a particularly useful technique
in this endeavor, providing information
about likely binding sites on the chemo-
kines for the receptor peptides (Duma
et al., 2007; Schnur et al., 2013) as well
as specific inter-protein contacts, allow-
ing previous NMR structure determina-
tions for CXC subfamily chemokines
CXCL8 (interleukin 8 [IL-8]) and CXCL12
(SDF-1) with a peptide from their respec-
tive receptors (Skelton et al., 1999, Veld-
kamp et al., 2008).
In this issue of Structure, Millard et al.
(2014) report the first structure of a CC
chemokine in complex with a receptor
peptide, namely the chemokine CCL11
(eotaxin-1) with a sulfated peptide
(Su1617) derived from the N terminus of
the receptor CCR3. The researchers
have obtained 55 intermolecular contacts
(as well as numerous intramolecular con-
tacts), leading to a complex structureStructure 22, November 4, 2014with a clearly delineated binding sur-
face on the chemokine for its receptor,
composed of the N-loop and b2-b3 region
from CCL11 (Figure 1). The Su1617-
bound CCL11 remained similar to its free
form, an observation also noted by previ-
ous reports of other chemokine:peptide
complexes. Notably, the sidechains of
sulfated tyrosine residues 16 and 17 on
the receptor peptide are positioned to
interact with regions on the chemokine
that include important basic, hydropho-
bic, and aromatic residues that can form
salt bridge, hydrophobic, and cation-p
interactions, respectively. Further muta-
genesis studies by the authors confirmed
the importance of the basic residues on
CCL11.
This newly described structure extends
our understanding of chemokine:receptor
interactions, providing an atomic resolu-
tion picture as well as validating the
importance of tyrosine sulfation of che-
mokine receptors. It also supports the
prevailing ‘‘two-site model’’ of receptor
binding, in which the N terminus of the re-
ceptor is bound by the chemokine N-loop
and b2-b3 regions first, likely followed by
the N terminus of the chemokine ligand
interacting with the extracellular loops
and/or transmembrane segments of the
receptor for activation and intracellular
signaling.
The authors also gathered recent re-
ports from several groups to summarize
and compare chemokine:receptor inter-
actions as they are currently understood.
Similarities have been found among these
structures, including sulfated tyrosine res-
idues from the receptor peptide interact-
ing with similar binding surfaces on the
chemokines. More interestingly, it was
noted that there appears to be a clear dif-
ference in the orientation of the chemo-
kine relative to its receptor among these
structures.
While the present results and contex-
tual comparisons are of great value,
some questions remain. For example,
probably one of the most important che-
mokine residues known for receptor affin-
ity for many CC chemokines is the residue
immediately following the conserved CC
motif, frequently being an aromatic resi-
due (Phe11 in CCL11). In the current
structure, the Phe11 residue does not
appear to make direct contact with the
receptor peptide. It is also noted that
chemokines bind to intact receptorsª2014 Elsevier Ltd All rights reserved 1551
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Previewsmuch more tightly than the peptides
derived from receptor N terminus. These
observations led the authors to suggest
a possible role for this residue in ‘‘site 2’’
receptor interactions (as opposed to the
‘‘site 1’’ interactions illustrated by the
present structure). Potentially more sig-
nificant is the apparent variation in the
chemokine orientation to the receptor of
the three known structures (the current
CCL11:CCR3 peptide, CXCL8:CXCR1
peptide, and CXCL12:CXCR4 peptide).
One may wonder whether the chemo-
kines would be positioned differently
on the full length receptor than with a
sulfated peptide. If the orientation differ-
ence observed in these studies reflect
the actual positioning of these molecules,
this suggests that there may be distinct
binding patterns by individual chemoki-1552 Structure 22, November 4, 2014 ª2014ne:receptor pairs, which in turn may pro-
vide an explanation for the variety of
signaling/activation outcomes.
To fully address these questions, struc-
tures of chemokines in complex with their
full length receptors are needed. As the
structure determination of chemokine re-
ceptors in complex with their chemokine
ligands becomes more likely, this goal
may be met in the near future.REFERENCES
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